{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:33:26Z","timestamp":1787322806987,"version":"build-2736575974"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the standard of care after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS). Although aspirin discontinuation after at least 1 month of DAPT reduces bleeding without increasing ischemic events, the safety of aspirin withdrawal before the first 30 days after PCI remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Online databases were searched through December 2025 to identify randomized controlled trials comparing aspirin-free P2Y12 inhibitor monotherapy initiated within 30 days after PCI versus standard DAPT in ACS patients. Outcomes were assessed during short-term (0\u201330 days) and longer-term follow-up (31 days to 12 months). Random-effects models were used to estimate odds ratios (ORs) with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Three randomized controlled trials comprising 10,736 patients were included. Within 30 days after PCI, aspirin discontinuation was associated with a higher risk of myocardial infarction (OR, 2.12; 95% CI, 1.31\u20133.44), without a reduction in bleeding compared with DAPT. No significant differences were observed in other ischemic, composite, or mortality outcomes. During longer-term follow-up, P2Y12 inhibitor monotherapy was associated with significant reductions in bleeding outcomes and net adverse clinical events, without an increase in ischemic outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In ACS patients undergoing PCI with drug-eluting stent, aspirin discontinuation within 30 days did not reduce bleeding and was associated with a higher risk of myocardial infarction. These findings suggest the first 30 days after PCI may represent a period of heightened ischemic vulnerability, and routine aspirin withdrawal during this early phase should be interpreted with caution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/hpc.0000000000000425","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:26:31Z","timestamp":1787318791000},"page":"e0425","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Aspirin Withdrawal Before 30 Days After PCI in Acute Coronary Syndrome and Early Myocardial Infarction Risk: A Systematic Review and Meta-analysis"],"prefix":"10.1097","volume":"25","author":[{"given":"Khubaib Mohammad","family":"Murtafa","sequence":"first","affiliation":[{"name":"Government Medical College, Srinagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadiya Sajad","family":"Khanday","sequence":"additional","affiliation":[{"name":"Government Medical College, Srinagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Sameem","family":"Arif","sequence":"additional","affiliation":[{"name":"Government Medical College, Srinagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir Wajid","family":"Majeed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, VMMC and Safdarjung Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrukh","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kakatiya Medical College, Warangal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumaan Rafiq","family":"Mir","sequence":"additional","affiliation":[{"name":"Government Medical College, Srinagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shariq Ahmad","family":"Wani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Wayne State University, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merruna Liqua","family":"Chishti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Al-Falah School of Medical Sciences and Research Centre, Faridabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabin Dilshad","family":"Kawoosa","sequence":"additional","affiliation":[{"name":"Government Medical College, Srinagar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachita","family":"Kour","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Pennsylvania, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Hamid","family":"Changal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, MercyOne Siouxland Medical Centre, Sioux City, IA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"R1-20260821","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.123.067767","article-title":"Antiplatelet therapy after PCI: the Art and science of de-escalation.","volume":"149","author":"Storey","year":"2024","journal-title":"Circulation"},{"key":"R2-20260821","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/jama.2021.0716","article-title":"Oral antiplatelet therapy after acute coronary syndrome: a review.","volume":"325","author":"Kamran","year":"2021","journal-title":"JAMA"},{"key":"R3-20260821","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines.","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"R4-20260821","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-thoracic Surgery (EACTS).","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"R5-20260821","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","article-title":"Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology.","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"key":"R6-20260821","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial.","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"R7-20260821","doi-asserted-by":"crossref","first-page":"e015560","DOI":"10.1161\/JAHA.119.015560","article-title":"Efficacy and safety of ticagrelor monotherapy by clinical presentation: pre-specified analysis of the GLOBAL LEADERS trial.","volume":"10","author":"Vranckx","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"R8-20260821","doi-asserted-by":"crossref","first-page":"e012004","DOI":"10.1161\/CIRCINTERVENTIONS.122.012004","article-title":"clopidogrel monotherapy after 1-month dual antiplatelet therapy in percutaneous coronary intervention: from the STOPDAPT-2 total cohort.","volume":"15","author":"Obayashi","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"R9-20260821","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1093\/eurheartj\/ehaa670","article-title":"Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.","volume":"41","author":"Baber","year":"2020","journal-title":"Eur Heart J"},{"key":"R10-20260821","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial.","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"R11-20260821","doi-asserted-by":"crossref","first-page":"e036642","DOI":"10.1161\/JAHA.124.036642","article-title":"P2Y12 inhibitor-based single antiplatelet therapy versus conventional dual antiplatelet therapy after newer-generation drug-eluting stent implantation in chronic and acute coronary syndromes: a systematic review and meta-analysis of randomized clinical trials.","volume":"14","author":"Iglesias","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"R12-20260821","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamacardio.2024.0133","article-title":"Ticagrelor or clopidogrel monotherapy vs dual antiplatelet therapy after percutaneous coronary intervention: a systematic review and patient-level meta-analysis.","volume":"9","author":"Valgimigli","year":"2024","journal-title":"JAMA Cardiol"},{"key":"R13-20260821","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jacc.2022.11.041","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions.","volume":"81","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R14-20260821","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.120.046251","article-title":"The safety and efficacy of aspirin discontinuation on a background of a P2Y12 inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis.","volume":"142","author":"O\u2019Donoghue","year":"2020","journal-title":"Circulation"},{"key":"R15-20260821","first-page":"1381","article-title":"Ticagrelor monotherapy following short-term DAPT in ACS undergoing PCI: a systematic review and meta-analysis.","volume":"105","author":"Guzman","year":"2025","journal-title":"Catheter Cardiovasc Interv"},{"key":"R16-20260821","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/eurheartj\/ehac829","article-title":"Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis.","volume":"44","author":"Kang","year":"2023","journal-title":"Eur Heart J"},{"key":"R17-20260821","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur Heart J"},{"key":"R18-20260821","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1253\/circj.CJ-21-0016","article-title":"Effects of acute coronary syndrome and stable coronary artery disease on bleeding and ischemic risk after percutaneous coronary intervention.","volume":"85","author":"Natsuaki","year":"2021","journal-title":"Circ J"},{"key":"R19-20260821","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/eurheartj\/ehx255","article-title":"Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy.","volume":"39","author":"Doll","year":"2018","journal-title":"Eur Heart J"},{"key":"R20-20260821","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4244\/EIJ-D-22-00886","article-title":"Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study.","volume":"19","author":"van der Sangen","year":"2023","journal-title":"EuroIntervention"},{"key":"R21-20260821","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1253\/circj.CJ-23-0051","article-title":"Prasugrel monotherapy after percutaneous coronary intervention with biodegradable-polymer platinum-chromium everolimus eluting stent for Japanese patients with chronic coronary syndrome (ASET-JAPAN).","volume":"87","author":"Muramatsu","year":"2023","journal-title":"Circ J"},{"key":"R22-20260821","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jcin.2020.06.023","article-title":"Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable CAD: the ASET pilot study.","volume":"13","author":"Kogame","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"R23-20260821","doi-asserted-by":"crossref","first-page":"e35741","DOI":"10.1016\/j.heliyon.2024.e35741","article-title":"Aspirin-free P2Y12 inhibitor monotherapy immediately after percutaneous coronary intervention: a systematic review.","volume":"10","author":"Yu","year":"2024","journal-title":"Heliyon"},{"key":"R25-20260821","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R26-20260821","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews.","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"R27-20260821","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R28-20260821","doi-asserted-by":"crossref","first-page":"ehaf1050","DOI":"10.1093\/eurheartj\/ehaf1050","article-title":"Prasugrel or ticagrelor monotherapy vs dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndromes: a landmark analysis from the NEOMINDSET trial.","volume":"19","author":"Tavares","year":"2025","journal-title":"Eur Heart J"},{"key":"R29-20260821","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial.","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"key":"R30-20260821","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial.","volume":"149","author":"Natsuaki","year":"2024","journal-title":"Circulation"},{"key":"R31-20260821","first-page":"3286","article-title":"One-year outcomes of short-term dual antiplatelet therapy following percutaneous coronary intervention with drug-eluting stents: a meta-analysis of randomized clinical trials.","volume":"106","author":"Fretz","year":"2025","journal-title":"Catheter Cardiovasc Interv"},{"key":"R32-20260821","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamacardio.2024.3216","article-title":"Short-Term dual antiplatelet therapy after drug-eluting stenting in patients with acute coronary syndromes: a systematic review and network meta-analysis.","volume":"9","author":"Carvalho","year":"2024","journal-title":"JAMA Cardiol"},{"key":"R33-20260821","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s40265-013-0126-z","article-title":"Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.","volume":"73","author":"Ferri","year":"2013","journal-title":"Drugs"},{"key":"R34-20260821","first-page":"S1553","article-title":"Prasugrel monotherapy versus 12-month dual antiplatelet therapy in STEMI patients undergoing intravascular imaging-guided PCI: Study design and rationale of the randomized PREMIUM trial.","volume":"11","author":"Takahashi","year":"2025","journal-title":"Cardiovasc Revasc Med"},{"key":"R35-20260821","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2147\/TCRM.S92222","article-title":"New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism.","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"R36-20260821","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1055\/s-0038-1649484","article-title":"Peri-procedural platelet reactivity in percutaneous coronary intervention.","volume":"118","author":"Alexopoulos","year":"2018","journal-title":"Thromb Haemost"},{"key":"R37-20260821","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.3390\/cells10061391","article-title":"Inflammation during percutaneous coronary intervention-prognostic value, mechanisms and therapeutic targets.","volume":"10","author":"Tucker","year":"2021","journal-title":"Cells"},{"key":"R38-20260821","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12872-025-04765-x","article-title":"Abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.","volume":"25","author":"Soleimani","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"R39-20260821","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk.","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/HPC.0000000000000425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:26:37Z","timestamp":1787318797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/HPC.0000000000000425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/hpc.0000000000000425","relation":{},"ISSN":["1535-2811"],"issn-type":[{"value":"1535-2811","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}